2025 年第 7 期 第 20 卷

肝细胞肝癌患者长链非编码RNA SH3BP5-AS1和微小RNA-6838-5p的表达及临床意义研究

Expression and clinical significance of long non-coding RNA SH3BP5-AS1 and microRNA-6838-5p in hepatocellular carcinoma patients

作者：张彤1平胜2李贞贞1马莉3

英文作者：Zhang Tong1 Ping Sheng2 Li Zhenzhen1 Ma Li3

单位：1西安交通大学第二附属医院检验科，西安710004；2西电集团医院普外科，西安710082；3西安交通大学第二附属医院病理科，西安710004

英文单位：1Department of Clinical Laboratory The Second Affiliated Hospital of Xi′an Jiaotong University Xi′an 710004 China; 2Department of General Surgery XD Group Hospital Xi′an 710082 China; 3Department of Pathology The Second Affiliated Hospital of Xi′an Jiaotong University Xi′an 710004 China

关键词：肝细胞肝癌；临床病理特征；长链非编码RNASH3BP5-AS1；微小RNA-6838-5p

英文关键词：Hepatocellularcarcinoma;Clinicopathologicalfeature;Longnon-codingRNASH3BP5-AS1;MicroRNA-6838-5p

• 摘要：

• 目的 探讨肝细胞肝癌患者长链非编码RNA（lncRNA）SH3BP5-AS1和微小RNA（miR）-6838-5p的表达及其与临床病理特征和预后的关系。方法 选取2018年1月至2020年12月西安交通大学第二附属医院、西电集团医院收治的行手术治疗的110例肝细胞肝癌患者。检测手术切除的癌组织和癌旁组织中lncRNA SH3BP5-AS1、miR-6838-5p表达，出院后随访患者生存情况。分析癌组织中lncRNA SH3BP5-AS1与miR-6838-5p相关性，绘制Kaplan-Meier曲线比较不同lncRNA SH3BP5-AS1与miR-6838-5p表达情况肝细胞肝癌患者的生存差异，单因素和多因素Cox风险比例回归方法分析影响肝细胞肝癌患者预后因素。结果 肝细胞肝癌组织中lncRNA SH3BP5-AS1表达高于癌旁组织，miR-6838-5p表达低于癌旁组织［（2.7±0.4）比（1.5±0.3）、（1.9±0.5）比（3.1±0.7）］（均P＜0.001）。lncRNA SH3BP5-AS1高表达、miR-6838-5p低表达与低分化、TNM分期Ⅲ期、肝内转移、血管侵犯有关（均P＜0.05）。肝细胞肝癌组织中lncRNA SH3BP5-AS1与miR-6838-5p表达呈负相关（r=-0.524，P＜0.001）。lncRNA SH3BP5-AS1高表达肝细胞肝癌患者3年总生存率低于lncRNA SH3BP5-AS1低表达患者，miR-6838-5p低表达肝细胞肝癌患者3年总生存率低于miR-6838-5p高表达患者（均P＜0.05）。TNM分期Ⅲ期、肝内转移、高表达lncRNA SH3BP5-AS1为肝细胞肝癌患者预后不良的危险因素，高表达miR-6838-5p为保护因素（均P＜0.05）。结论 肝细胞肝癌组织中lncRNA SH3BP5-AS1表达上调、miR-6838-5p表达下调，与临床恶性病理特征以及预后不良有关。

• Objective  To investigate the expression of long non-coding RNA(lncRNA) SH3BP5-AS1 and microRNA(miR)-6838-5p in patients with hepatocellular carcinoma and their relationship with clinicopathological features and prognosis. Methods A total of 110 patients with hepatocellular carcinoma who underwent surgical treatment in The Second Affiliated Hospital of Xi′an Jiaotong University and XD Group Hospital from January 2018 to December 2020 were selected. The expressions of lncRNA SH3BP5-AS1 and miR-6838-5p in surgically resected cancer tissues and adjacent tissues were detected, and the survival of patients was followed up after discharge. The correlation between lncRNA SH3BP5-AS1 and miR-6838-5p in cancer tissues was analyzed, and Kaplan-Meier curve was drawn to compare the survival difference of hepatocellular carcinoma patients with different lncRNA SH3BP5-AS1 and miR-6838-5p expression. Univariate and multivariate Cox proportional hazards regression methods were used to analyze the prognostic factors of patients with hepatocellular carcinoma. Results The expression of lncRNA SH3BP5-AS1 in hepatocellular carcinoma tissues was higher than that in adjacent tissues, and the expression of miR-6838-5p was lower than that in adjacent tissues ［(2.7±0.4) vs (1.5±0.3), (1.9±0.5) vs (3.1±0.7)］(both P<0.001). High expression of lncRNA SH3BP5-AS1 and low expression of miR-6838-5p were associated with poor differentiation, TNM stage Ⅲ, intrahepatic metastasis and vascular invasion (all P<0.05). There was a negative correlation between lncRNA SH3BP5-AS1 and miR-6838-5p expression in hepatocellular carcinoma tissues (r=-0.524, P<0.001). The 3-year overall survival rate of hepatocellular carcinoma patients with high expression of lncRNA SH3BP5-AS1 was lower than that of patients with low expression of lncRNA SH3BP5-AS1, and the 3-year overall survival rate of hepatocellular carcinoma patients with low expression of miR-6838-5p was lower than that of patients with high expression of miR-6838-5p (both P<0.05). TNM stage Ⅲ, intrahepatic metastasis and high expression of lncRNA SH3BP5-AS1 were risk factors for poor prognosis of patients with hepatocellular carcinoma, and high expression of miR-6838-5p was a protective factor (all P<0.05). Conclusion Up-regulation of lncRNA SH3BP5-AS1 expression and down-regulation of miR-6838-5p expression in hepatocellular carcinoma tissues are related to clinical malignant pathological characteristics and poor prognosis.